Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacy

Peptides ◽  
2014 ◽  
Vol 62 ◽  
pp. 176-182 ◽  
Author(s):  
Zachary M. Novakovic ◽  
Brian M. Anderson ◽  
Patricia Grasso
2020 ◽  
Vol 16 (3) ◽  
pp. 272-306
Author(s):  
Ioannis Fotopoulos ◽  
Dimitra Hadjipavlou-Litina

Background: Coumarins exhibit a plethora of biological activities, e.g. antiinflammatory and anti-tumor. Molecular hybridization technique has been implemented in the design of novel coumarin hybrids with several bioactive groups in order to obtain molecules with better pharmacological activity and improved pharmacokinetic profile. Objective: Therefore, we tried to gather as many as possible biologically active coumarin hybrids referred in the literature till now, to delineate the structural characteristics in relation to the activities and to have a survey that might help the medicinal chemists to design new coumarin hybrids with drug-likeness and varied bioactivities. Results: The biological activities of the hybrids in most of the cases were found to be different from the biological activities presented by the parent coumarins. The results showed that the hybrid molecules are more potent compared to the standard drugs used in the evaluation experiments. Conclusion: Conjugation of coumarin with varied pharmacophore groups/druglike molecules responsible for different biological activities led to many novel hybrid molecules, with a multitarget behavior and improved pharmacokinetic properties.


2004 ◽  
Vol 78 (4) ◽  
pp. 2088-2099 ◽  
Author(s):  
Patrick Tremblay ◽  
Haydn L. Ball ◽  
Kiyotoshi Kaneko ◽  
Darlene Groth ◽  
Ramanujan S. Hegde ◽  
...  

ABSTRACT Gerstmann-Sträussler-Scheinker (GSS) disease is a dominantly inherited, human prion disease caused by a mutation in the prion protein (PrP) gene. One mutation causing GSS is P102L, denoted P101L in mouse PrP (MoPrP). In a line of transgenic mice denoted Tg2866, the P101L mutation in MoPrP produced neurodegeneration when expressed at high levels. MoPrPSc(P101L) was detected both by the conformation-dependent immunoassay and after protease digestion at 4°C. Transmission of prions from the brains of Tg2866 mice to those of Tg196 mice expressing low levels of MoPrP(P101L) was accompanied by accumulation of protease-resistant MoPrPSc(P101L) that had previously escaped detection due to its low concentration. This conformer exhibited characteristics similar to those found in brain tissue from GSS patients. Earlier, we demonstrated that a synthetic peptide harboring the P101L mutation and folded into a β-rich conformation initiates GSS in Tg196 mice (29). Here we report that this peptide-induced disease can be serially passaged in Tg196 mice and that the PrP conformers accompanying disease progression are conformationally indistinguishable from MoPrPSc(P101L) found in Tg2866 mice developing spontaneous prion disease. In contrast to GSS prions, the 301V, RML, and 139A prion strains produced large amounts of protease-resistant PrPSc in the brains of Tg196 mice. Our results argue that MoPrPSc(P101L) may exist in at least several different conformations, each of which is biologically active. Such conformations occurred spontaneously in Tg2866 mice expressing high levels of MoPrPC(P101L) as well as in Tg196 mice expressing low levels of MoPrPC(P101L) that were inoculated with brain extracts from ill Tg2866 mice, with a synthetic peptide with the P101L mutation and folded into a β-rich structure, or with prions recovered from sheep with scrapie or cattle with bovine spongiform encephalopathy.


MedChemComm ◽  
2016 ◽  
Vol 7 (6) ◽  
pp. 1082-1092 ◽  
Author(s):  
Shinya Fujii

Interactions between biologically active compounds and their targets often involve hydrophobic interactions, and hydrophobicity also influences the pharmacokinetic profile.


2021 ◽  
Vol 28 ◽  
Author(s):  
Tommaso Felicetti ◽  
Maria Chiara Pismataro ◽  
Violetta Cecchetti ◽  
Oriana Tabarrini ◽  
Serena Massari

Viruses are a continuing threat to global health. The lack or limited therapeutic armamentarium against some viral infections and increasing drug resistance issues make the search for new antiviral agents urgent. In recent years, a growing literature highlighted the use of triazolopyrimidine (TZP) heterocycles in the development of antiviral agents, with numerous compounds that showed potent antiviral activities against different RNA and DNA viruses. TZP core represents a privileged scaffold for achieving biologically active molecules, thanks to: i) the synthetic feasibility that allows to variously functionalize TZPs in the different positions of the nucleus, ii) the ability of TZP core to establish multiple interactions with the molecular target, and iii) its favorable pharmacokinetic properties. In the present review, after mentioning selected examples of TZP-based compounds with varied biological activities, we will focus on those antivirals that appeared in the literature in the last 10 years. Approaches used for their identification, the hit-to-lead studies, and the emerged structure-activity relationship will be described. A mention of the synthetic methodologies to prepare TZP nuclei will also be given. In addition, their mechanism of action, the binding mode within the biological target, and pharmacokinetic properties will be analyzed, highlighting the strengths and weaknesses of compounds based on the TZP scaffold, which is increasingly used in medicinal chemistry.


Author(s):  
Pérez-Etcheverry Diana ◽  
Lorenzo-Ferreiro Carmen

<p><strong>Aim</strong>: To construct an express a mouse-human chimeric antibody against IL-23p19 using a<br />synthetic peptide as immunogen.</p><p><strong>Methods</strong>: Immunization of mice with a synthetic peptide derived from the IL-23p19 sequence and generation of hybridoma secreting specific antibodies. The chimeric antibody was created using two eukaryotic plasmid constructions; one of them carrying the light mouse-human chain and the other the heavy mouse-human chain. CHO-K1 cells were cotransfected with both plasmids and stable transfectants were grown in selective culture medium.</p><p><strong>Results</strong>: A chimeric version of anti-IL-23p19 was successfully constructed and expressed in eukaryotic cells. The expressed chimeric antibody showed specific recognition not only of the peptide used as immunogen but also the subunit p19 and the complete interleukin Il-23.</p><p><strong>Conclusion</strong>: A Chimeric antibody that was developed against a synthetic peptide, which is able to recognize the parent protein IL23 biologically active, could be developed into a targeted therapy in diseases with chronic inflammation.</p>


Sign in / Sign up

Export Citation Format

Share Document